Regulus Therapeutics (RGLS) Financials

$8.16

$0.00 (0.00%)

As on 25-Jun-2025 09:30EDT

Market cap

$565 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	0.34	--	--	--	0.01	10.01
Cost of Revenue	0.26	--	21.15	0.12	0.46	0.02
Gross Profit	0.08	--	-21.15	-0.12	-0.46	10.01
Operating Expenses	51.67	50.04	9.96	28.24	27.82	24.16
Operating Profit (EBIT)	-51.75	-50.04	-31.11	-28.24	-27.82	-14.16
Other Income	--	--	--	--	--	0.23
Profit before Tax	-47.52	-46.36	-30.04	-28.32	-27.81	-15.73
Provision for Tax	-14.06	0.00	0.00	0.00	0.00	-0.47
Profit after Tax (Net Income)	-47.52	-46.36	-30.04	-28.32	-27.81	-15.26
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-28.32	-27.81	-15.73

Liabilities ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	69.03	76.41	21.19	33.29	54.96	26.03
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1.40	0.27	1.06	1.77	8.27	5.19
Current Liabilities	4.40	7.50	8.51	11.66	5.23	11.58
Total Liabilities	79.22	84.18	30.75	46.72	68.45	37.60

Assets ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	3.13	1.84	2.57	2.64	3.22	0.87
Current Assets	71.69	82.35	28.18	44.08	65.24	36.73
Total Assets	79.22	84.18	30.75	46.72	68.45	37.60
Total Debt*	1.40	0.27	2.39	6.28	7.09	4.65
Net Current Assets	67.30	74.85	19.67	32.42	60.01	25.15

Cashflow ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	--	-41.67	-26.77	-25.53	-24.13	-12.54
Cash Flow from Investing Activities	--	-35.98	14.49	-15.12	-0.25	-0.01
Cash from Financing Activities	--	92.42	11.82	4.49	53.74	9.51
Net Cash Inflow / Outflow	--	--	--	--	--	-3.03

Financials Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-0.73	-0.71	-1.49	-1.68	-2.60	-3.20
Cash EPS ($)	--	-0.70	-1.48	-1.67	-2.56	-3.10
Adjusted Book Value ($)	--	1.17	1.05	1.98	5.14	5.45
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.64	-1.32	-1.52	-2.26	-2.63
Free Cash Flow per Share ($)	--	-0.64	-1.35	-1.54	-2.28	-2.63

Profitability Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	--	-92.48	-95.14	-55.74	-59.98	-46.69
ROE (%)	-60.99	-95.00	-110.27	-64.19	-68.68	-66.30
ROA (%)	-48.48	-80.67	-77.55	-49.18	-52.44	-38.31
EBIT Margin (%)	-14,879.41	--	--	--	-277,549.39	-141.47
Net Margin (%)	-13,977.35	--	--	--	-277,469.57	-149.07
Cash Profit Margin (%)	-0.04	--	--	--	--	--

Growth Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	12.58	--	--	-1.00	-1.00	0.46
EBIT Growth (%)	-63.90	-48.51	-10.16	-1.52	-96.51	15.91
Net Profit Growth (%)	-51.51	-54.34	-6.05	-1.85	-82.19	17.91
EPS Growth (%)	50.18	0.52	0.12	0.35	0.19	0.64
Book Value Growth (%)	-72.13	--	--	--	--	--

Valuation Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	--	-2.23	-0.86	-0.81	-0.12	-0.42
Price / Book Value	8.19	1.35	1.22	0.69	0.06	0.25
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.57	-0.61	-0.15	0.35	1.82	1.46
Close Price ($)	1.75	1.58	1.28	1.37	3.15	13.50
High Price ($)	2.91	3.79	2.14	3.70	23.20	17.40
Low Price ($)	0.83	1.08	0.76	1.08	3.15	4.22
Market Cap ($ Cr)	564.95	--	--	--	--	--

Solvency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	--	0.00	0.11	0.19	0.13	0.18
Short term debt to equity ratio	--	--	0.06	0.14	0.01	0.18
Current Ratio	16.31	10.98	3.31	3.78	12.48	3.17
Quick Ratio	16.31	--	2.96	3.78	12.48	2.89
Interest Coverage	-509.99	-292.40	-51.50	-41.05	-32.53	-7.83

Operating Efficiency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	--	--	--	--	30,622.53	5.03
Asset Turnover	0.00	--	--	--	0.00	0.25
Receivable days	--	--	--	--	65,090.27	30.01
Inventory Days	--	--	26.01	9.01	1,319.76	86,130.17
Payable days	--	--	3.27	688.59	326.26	22,085.88
Cash Conversion Cycle	--	--	--	--	66,083.77	64,074.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.